Submit Deal

TECELRA

Summary

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 64 M

Avg. Deal Size£ 64 M

Market Context

Sort

04 Aug 2025|United Kingdom|Biotechnology

Target: TECELRA

Bidder: US WORLDMEDS

6 Service Providers

2 Bidder | 4 Vendor

4 Dealmakers

2 Bidder | 2 Vendor

£ 64 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy